Form 4: Lyell Immunopharma Director Cathy Friedman Reports Acquisition of Stock Options

Director Cathy Friedman reports acquisition of 130,000 stock options in Lyell Immunopharma, Inc.

Summary

• Cathy Friedman, a director of Lyell Immunopharma, Inc., filed a Form 4 disclosing changes in beneficial ownership.
• The report indicates the acquisition of 130,000 stock options with an exercise price of $0.4017 on May 15, 2025.
• These options vest on the earlier of the next annual stockholder meeting following May 15, 2025, or the first anniversary of that date, contingent on continuous service.
• Friedman also indirectly owns 236,370 shares of common stock through the Duane Family Trust and 100,000 shares through The Duane Irrevocable Trust 2020, for which she serves as a trustee.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition, which doesn't inherently indicate positive or negative sentiment but suggests confidence from the director.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent on future events, specifically the next annual meeting of stockholders or the first anniversary of May 15, 2025, and continuous service as a director.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates changes in Cathy Friedman's beneficial ownership of Lyell Immunopharma stock.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder confidence.

Key Dates

Keywords

Lyell Immunopharma, Cathy Friedman, Form 4, Stock Options, Beneficial Ownership, Director